TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Walnut Oral Immunotherapy for Tree Nut Allergy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age 6 to 45 years, either sex, any race, any ethnicity with a convincing clinical history of walnut or another tree nut allergy and either a positive prick skin test (≥ 3mm) or serologic evidence of allergic sensitization (defined as specific IgE \> 0.35 kU/L) to walnut and at least one other tree nut.~* A positive 2000 mg oral food challenge at enrollment to walnut and to one other tree nut.~* Written informed consent from participant and/or parent/guardian~* Written assent from all subjects as appropriate~* All females of child bearing age must be using appropriate birth control~Exclusion Criteria:~* History of severe anaphylaxis to walnut or other tree nuts, defined as symptoms associated with hypoxia, hypotension or neurologic compromise (cyanosis or SpO2 \< 92% at any stage, hypotension, confusion, collapse, loss of consciousness; or incontinence).~* Known allergy to oat~* Chronic disease (other than asthma, atopic dermatitis, rhinitis) requiring therapy or other respiratory or medical conditions deemed by the investigator to put the subject at increased risk of anaphylaxis or poor outcomes from receiving OIT or undergoing food challenge.~* Poor control or persistent activation of atopic dermatitis~* Active eosinophilic or other inflammatory (e.g., celiac) gastrointestinal disease in the past 2 years.~* Participation in any interventional study for food allergy in the past 6 months~* Participant is on build-up phase of immunotherapy (i.e., has not reached maintenance dosing).~* Severe asthma (2007 NHLBI Criteria Steps 5 or 6, see Appendix 2) or poorly controlled mild or moderate asthma~* Inability to discontinue antihistamines for initial day escalation, skin testing or OFC~* Use of omalizumab or other non-traditional forms of allergen immunotherapy (e.g., oral or sublingual) or immunomodulator therapy (not including corticosteroids) or biologic therapy within the past year~* Use of beta-blockers (oral), angiotensin-converting enzyme (ACE) inhibitors, angiotensin-receptor blockers (ARB) or calcium channel blockers~* Pregnancy or lactation

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Walnut Protein Powder (Type: EXPERIMENTAL): 38 weeks on active walnut powder on blinded treatment phase
- Oat Powder (Type: PLACEBO_COMPARATOR): 38 weeks on placebo (oat) powder during blinded treatment phase
- Open-label Walnut Protein Powder (Type: OTHER): Open-label treatment with walnut protein powder up to week 298 of total treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ridaforolimus in Treatment of Sarcoma-SUCCEED (Sarcoma Multi-Center Clinical Evaluation of the Efficacy of Ridaforolimus)(8669-011 AM6)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of metastatic soft-tissue or bone sarcoma~* Ongoing complete response, partial response, or stable disease (RECIST) after a minimum of 4 cycles (and maximum of 12 months) of any one first, second, or third line of prior cytotoxic chemotherapy for metastatic disease~* Eastern Cooperative Oncology Group performance status of 0 or 1~* Adequate organ and bone marrow function~* Completed prior chemotherapy with last dose received at least 3 and up to 12 weeks prior to randomization~Exclusion Criteria:~* Prior therapy with rapamycin or rapamycin analogs~* Ongoing toxicity associated with prior anticancer therapy~* Another primary malignancy within the past three years~* Concomitant medications that induce or inhibit CYP3A~* Significant, uncontrolled cardiovascular disease

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ridaforolimus (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Ixekizumab in Participants With Active Psoriatic Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Presents with established diagnosis of active psoriatic arthritis for at least 6 months, and currently meets Classification for Psoriatic Arthritis (CASPAR) criteria~* Active psoriatic arthritis (PsA) defined as the presence of at least 3 tender and at least 3 swollen joints~* Presence of active psoriatic skin lesion or a personal history of plaque psoriasis (Ps)~* Men must agree to use a reliable method of birth control or remain abstinent during the study~* Women must agree to use reliable birth control or remain abstinent during the study and for at least 12 weeks after stopping treatment~Exclusion Criteria:~* Current or prior use of biologic agents for treatment of Ps or PsA~* Inadequate response to greater than or equal to 4 conventional disease-modifying antirheumatic drugs (DMARDs)~* Current use of more than one conventional DMARD~* Evidence of active inflammatory arthritic syndromes or spondyloarthropathies other than PsA~* Have participated in any study with interleukin 17 (IL-17) antagonists, including ixekizumab~* Serious disorder or illness other than psoriatic arthritis~* Serious infection within the last 3 months~* Breastfeeding or nursing (lactating) women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ixekizumab Q2W (Type: EXPERIMENTAL): Administered by 80 milligram (mg) subcutaneous (SC) injection every 2 weeks (Q2W).
- Ixekizumab Q4W (Type: EXPERIMENTAL): Administered by 80 mg SC injection every 4 weeks (Q4W).
- Placebo (Type: PLACEBO_COMPARATOR): Placebo for ixekizumab and placebo for adalimumab administered by SC injection.
- Adalimumab Q2W (Type: ACTIVE_COMPARATOR): Administered by 40 mg SC injection Q2W.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Comparing Sirolimus/Prograf vs Sirolimus/CsA in High-Risk Renal Transplant Recipients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~* Patients of African-American descent or patient with a history of multiple transplants and/or patients with a high panel reactive antibody lab test with a renal transplant from a cadaveric donor, a living unrelated donor or a living-related mismatched donor.~* Age \>= 13 years, weight \>= 40 kg~* Women must have a negative pregnancy test at study entry~Exclusion criteria~* Multiple organ transplants or double kidney transplants (pediatric en-bloc or double adult)~* Active systemic infection, or localized major infection or known HIV~* Patients with residual kidney function \>20 mL/min

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Moderate to Severe Lateral Canthal Lines and Glabellar Lines Alone or in Combination

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female 18 years of age or older.~2. Moderate to severe LCL at maximum smile as assessed by the Investigator.~3. Moderate to severe LCL at maximum smile as assessed by the subject.~4. Moderate to severe GL at maximum frown as assessed by the Investigator.~5. Moderate to severe GL at maximum frown as assessed by the subject~Exclusion Criteria:~1. Previous use of any Botulinum toxin in facial areas within 9 months prior to study treatment.~2. Female who is pregnant, breast feeding, or intends to conceive a child during the study.~3. Known allergy or hypersensitivity to any component of the investigational product (QM1114-DP).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- QM1114-DP in the LCL + Placebo in the GL (Type: EXPERIMENTAL): QM1114-DP, a Botulinum Toxin Type A (BoNT-A) ; Mode of administration: intramuscular injection
- Placebo in the LCL and GL (Type: PLACEBO_COMPARATOR): A buffered solution; Mode of administration:~intramuscular injection
- Placebo in the LCL + QM1114-DP in the GL (Type: EXPERIMENTAL): QM1114-DP, a Botulinum Toxin Type A (BoNT-A) or placebo Mode of administration: intramuscular injection
- QM1114-DP in the LCL + GL (Type: EXPERIMENTAL): QM1114-DP, a Botulinum Toxin Type A (BoNT-A) ; Mode of administration: intramuscular injection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: DWI Offenders and Their Families App for Smartphones

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~DWI Offender~* male or female~* 21 years or older~* first-time DWI offender with IID installed in vehicle~* enrolled in Santa Fe County DWI Program~* have a smartphone, tablet computer, or personal computer with Internet access~* consent to participate~* able to read and speak English or Spanish~Concerned Family Member (CFM):~* male or female~* 21 years or older~* spouse, parent, or immediate family member of first-time DWI offender with IID installed in vehicle and enrolled in Santa Fe County DWI Program~* have a smartphone, tablet computer, or personal computer with Internet access~* consent to participate~* able to read and speak English or Spanish~Exclusion Criteria:~* other family members already enrolled in the project~* second or above DWI conviction

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Study Arms:
- Usual & Customary Information Group (Type: ACTIVE_COMPARATOR): Study Cohort Assessment:~Baseline 3 month follow-up/ post-test 9 month follow-up/post test \& Interlock Ignition Device
- B-SMART Intervention Group (Type: EXPERIMENTAL): Study Cohort Assessment:~Baseline Web App Intervention 3 month follow-up/ post-test 9 month follow-up/post test \& Interlock Ignition Device

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of a Metallic Cannula Versus A Standard Needle for Soft Tissue Augmentation of the Nasolabial Folds

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects agreeing to take part of the study, after being fully informed of the purpose and the nature of the investigation and after having signed the informed consent form~* Female subjects aged from 18 to 60~* Fitzpatrick phototype I to VI~* Presence of bilateral folds graded from 2 to 3 according to the Modified~* Fitzpatrick Wrinkle Scale~* Subjects that have never performed any treatment of nasolabial folds~* Female subjects of childbearing age that present a negative urine pregnancy test and are using an effective contraceptive method~* Subjects who will be available throughout the duration of the study~* Subjects with sufficient schooling and awareness to enable them to cooperate to the degree required by this protocol.~Exclusion Criteria:~* Use of systemic corticosteroids~* History of herpes in lip~* Inflammation or active infection in the area to be injected~* Any surgical treatment or cosmetic procedure in the area to be injected that interfere in study's outcomes~* Coagulation disorders or use of anticoagulants~* Previous hypersensitivity responses to Hyaluronic acid.~* Pregnant or women in breastfeeding, or women planning to become pregnant

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Metallic cannula (Type: EXPERIMENTAL): Nasolabial Fold with metallic cannula and hyaluronic acid injected. hyaluronic acid with metallic cannula or standard needle. Hyaluronic acid injected with the new tool
- Standard needle (Type: ACTIVE_COMPARATOR): Nasolabial Fold with standard needle and hyaluronic acid injected. hyaluronic acid with metallic cannula or standard needle.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dose Ranging Trial for Pixantrone in the FND-R Variant Regimen in Indolent Non-Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria~* Patients with relapsed or refractory indolent (low-grade) NHL~* Who have received 1-3 prior treatments with chemotherapy~Exclusion criteria~* Patients previously treated with fludarabine~* Prior treatment with rituximab (Rituxan), unless there was a complete response (CR) or partial response (PR) to that treatment~* Patients known to have an allergic reaction to rituximab, or to murine proteins.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Surface Stimulation for Female Sexual Dysfunction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult women ≥ 18 years of age~* Sexually active ≥ 1 time per month (≥ 2 times per month preferred)~* Score of 19 or less on a 6-question set of the Female Sexual Function Index (FSFI) survey~* Neurologically stable~* Ambulatory~* Capable of giving informed consent~* English speaking~* Capable and willing to follow study procedures~Exclusion Criteria:~* Men~* Women ≤ 17 years of age~* Pregnant or planning to get pregnant during the study period~* Clinically diagnosed neurological bladder dysfunction~* Prior experience with PTNS or DGNS~* Current use of transcutaneous electrical nerve stimulation (TENS) on pelvis, back, or legs~* Implanted pacemaker, defibrillator, spinal cord stimulator, or sacral root stimulator~* Taking flibanserin~* Taking any investigational drug~* History of neurologic diseases or impairments~* Any other factors that the investigators feel would place the patient at increased risk from this study

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Posterior Tibial Nerve Stimulation Group (Type: EXPERIMENTAL): Subjects in this group will have transcutaneous electrical nerve stimulation electrodes placed on the skin surface over their posterior tibial nerve, that is in the area of the ankle, and receive stimulation for 30 minutes in weekly sessions for 12 weeks.
- Dorsal Genital Nerve Stimulation Group (Type: EXPERIMENTAL): Subjects in this group will have transcutaneous electrical nerve stimulation electrodes placed on the skin surface over the dorsal genital nerve, that is above and/or on the lateral side of the clitoris, and receive stimulation for 30 minutes in weekly sessions for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Multi-Media Tool on Enrollment in Oncology Clinical Trials

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adult, English-speaking women and men~* Newly diagnosed with lung, gastric or pancreatic cancer~* Coming to the University of Chicago outpatient oncology clinics for their first oncology visit~There are no Exclusion Criteria.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Touchscreen Participants (Type: None): New lung, gastric and pancreatic cancer patients presenting to the University of Chicago outpatient oncology clinics, a large research institution located on Chicago's Southside, were identified for study accrual, using the electronic scheduling system.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Weekly Paclitaxel Plus Carboplatin in Preoperative Treatment of Breast Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Women aged ≥ 18 years and \< 70 years~* Karnofsky performance status (KPS) ≥ 70~* At least one measurable disease according to the RECIST. histologically confirmed invasive breast cancer (excluding inflammatory breast cancer), large operable (T≥3 cm and N0-1) or locally advanced breast cancer (T3-4N0-3 or T0-4N2-3)~* Biopsy specimens are available for ER, PgR and Her2 analysis~* Adequate bone marrow function: Neutrophil ≥ 1.5\*109/L; Hb ≥ 100g/L; PLT ≥ 100\*109/L~* An estimated life expectancy of at least 12 months~* Willing to take biopsy before neoadjuvant chemotherapy and patients must be accessible for treatment and follow-up~* Women with potential child-bearing must have a negative pregnancy test (urine or serum) within 7 days of drug administration and agree to use an acceptable method of birth control to avoid pregnancy for the duration of the study~* Written informed consent according to the GCP~Exclusion Criteria:~* Prior systemic or loco-regional treatment of breast cancer, including chemotherapy~* Metastatic breast cancer~* With a history of malignant tumor except uterine cervix cancer in situ or skin basal cell carcinoma~* Patients with medical conditions that indicate intolerant to neoadjuvant therapy and related treatment, including uncontrolled pulmonary disease, diabetes mellitis, severe infection, active peptic ulcer, coagulation disorder, connective tissue disease or myelo-suppressive disease~* inadequate liver function (bilirubin \> 1.0 times upper normal limit \[UNL\] and ALT and/or AST\> 1.5 UNL associated with alkaline phosphatase \> 2.5 UNL; inadequate renal function (creatinine \> 1.0 times UNL and in case of limit value, Creatinine clearance \< 60 ml/min)~* Contraindication for using dexamethasone~* History of congestive heart failure, uncontrolled or symptomatic angina pectoris, arrhythmia or myocardial infarction; poorly controlled hypertension (systolic BP \> 180 mmHg or diastolic BP \> 100 mmHg)~* Has peripheral neuropathy ≥ grade 1~* Patient is pregnant or breast feeding~* Known severe hypersensitivity to any drugs in this study~* Treatment with any investigational drugs within 30 days before the beginning of study treatment

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- paclitaxel plus carboplatin (PCb) Arm (Type: EXPERIMENTAL): 4 cycles of neoadjuvant paclitaxel plus carboplatin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Oral Health Education Interventions Among Seniors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Must be 55 years old or older.~2. May be new, regular, emergency patients attending the TUKSoD clinic at Kleinlife or clinics at the Dental School or utilizing medical and social services at Kleinlife who have the intention to become patients of record at the dental clinic.~3. Must be able to speak and understand English.~4. Must be willing to provide consent to participate in the study for himself/herself.~Exclusion Criteria:~1. Subjects younger than 55 years old will be excluded from the study.~2. Subjects who do not provide consent for participation will be excluded from the study.~3. Subjects who do not speak and understand English

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control: Standard of Care (Type: NO_INTERVENTION): Regular dental care under the standard clinic operation
- Intervention 1: Group-based oral health education (Type: EXPERIMENTAL): Group based oral health education
- Intervention 2: Individual-based oral health education (Type: EXPERIMENTAL): Individual-based motivational interviewing

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete